Your browser doesn't support javascript.
loading
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
Amarendra Pegu; Stephen D. Schmidt; Chloe A. Talana; Jim Albert; Evan Anderson; Hamilton Bennett; Kizzmekia Corbett; Britta Flach; Lisa Jackson; Brett Leav; Julie E. Ledgerwood; Catherine J. Luke; Mat Makowski; Paul C. Roberts; Mario Roederer; Paulina Alejandra Rebolledo; Christina A. Rostad; Nadine G. Rouphael; Lingshu Wang; Eun Sung Yang; John H. Beigel; Barney S. Graham; John R. Mascola; Adrian McDermott; Nicole A Doria-Rose.
Afiliação
  • Amarendra Pegu; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • Stephen D. Schmidt; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • Chloe A. Talana; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • Jim Albert; Emmes Company, Rockville, MD, USA.
  • Evan Anderson; Department of Medicine, Center for Childhood Infections and Vaccines (CCIV) of Childrens Healthcare of Atlanta and Emory University Department of Pediatrics, At
  • Hamilton Bennett; Moderna, Inc., Cambridge, MA, USA.
  • Kizzmekia Corbett; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • Britta Flach; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • Lisa Jackson; Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
  • Brett Leav; Moderna, Inc., Cambridge, MA, USA.
  • Julie E. Ledgerwood; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • Catherine J. Luke; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Mat Makowski; Emmes Company, Rockville, MD, USA.
  • Paul C. Roberts; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Mario Roederer; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • Paulina Alejandra Rebolledo; Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur, GA, USA.
  • Christina A. Rostad; Department of Medicine, Center for Childhood Infections and Vaccines (CCIV) of Childrens Healthcare of Atlanta and Emory University Department of Pediatrics, At
  • Nadine G. Rouphael; Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur, GA, USA.
  • Lingshu Wang; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • Eun Sung Yang; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • John H. Beigel; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Barney S. Graham; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • John R. Mascola; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • Adrian McDermott; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Vaccine Research Center,
  • Nicole A Doria-Rose; National Institutes of Health
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-444010
ABSTRACT
SARS-CoV-2 mutations may diminish vaccine-induced protective immune responses, and the durability of such responses has not been previously reported. Here, we present a comprehensive assessment of the impact of variants B.1.1.7, B.1.351, P.1, B.1.429, and B.1.526 on binding, neutralizing, and ACE2-blocking antibodies elicited by the vaccine mRNA-1273 over seven months. Cross-reactive neutralizing responses were rare after a single dose of mRNA-1273. At the peak of response to the second dose, all subjects had robust responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of mRNA-1273. Across all assays, B.1.351 had the greatest impact on antibody recognition, and B.1.1.7 the least. These data complement ongoing studies of clinical protection to inform the potential need for additional boost vaccinations. One-Sentence SummaryMost mRNA-1273 vaccinated individuals maintained binding and functional antibodies against SARS-CoV-2 variants for 6 months.
Licença
cc0
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint